Summary
A randomized controlled trial was performed to study the efficiency of adjuvant chemotherapy with carly intravesical instillation of Adriamycin and long-term oral administration of 5-fluorouracil in 275 patients with superficial bladder cancer. All of the patients were randomized into four groups. Group A received early (immediately and 2 days after transurethral resection) instillation of Adriamycin alone; Group B received early instillation of Adriamycin with oral administration of 5-fluorouracil; Group C received delayed (7 days after transurethral resection) instillation of Adriamycin alone; and group D received delayed instillation of Adriamycin with oral administration of 5-fluorouracil. All patients subsequently received instillations weekly for 2 weeks and then every 2 weeks for a further 14 weeks. After 4 months, they received monthly instillations for 8 months. 5-Fluorouracil (groups B and D) was given daily p.o. for 1 year. Evaluation was possible in 187 patients. The postoperative follow-up period for determination of non-recurrence rates was 36 months, during which no significant difference was detected among the four groups. Moreover, no statistically significant difference was found between the early-and delayed-instillation groups. However, the non-recurrence rates obtained in the groups undergoing early instillation were higher than those determined in the delayed-instillation groups during the 36-month follow-up period, and this difference was especially significant at 4 and 5 months. In addition, the early-instillation groups showed significantly higher non-recurrence rates than did the delayed-instillation groups in terms of primary cases (P<0.01), tumor size of <1 cm (P<0.05), multiple tumors (P<0.01), pathological stage pTa (P<0.01), and histological grades G1 and G2 (P<0.05). Groups B and D, which were treated by intravesical instillation of Adriamycin with oral administration of 5-fluorouracil, showed no significant prophylaxis of recurrence during the 36-month follow-up as compared with groups A and C, which received intravesical instilations alone. The main side effect, which required discontinuation of the treatment, was bladder irriation. However, no significant difference in its incidence was found between the early-and delayed-instillation groups. No severe systemic side effect was encountered in this study. These results suggest that early as well as repeated intravesical instillation of Adriamycin is clinically tolerable and may be effective in preventing the recurrence of superficial bladder cancer.
Similar content being viewed by others
References
Cross RJ, Glashan RW, Humphrey CS, Robinson MRG, Smith PH, Williams RE (1976) Treatment of advanced bladder cancer with Adriamycin and 5-fluorouracil. Br J Urol 48:609
Denis L, Bouffioux C, Kurth KH, Debruyne F, Sylvester R, De Pauw M, Members of the EORTC Urological Group (1987) Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overview. Cancer Chemother Pharmacol 20 [Suppl]:S67
Fosså SD, Gudmundsen TE (1981) Single drug chemotherapy with 5-FU and Adriamycin in metastatic bladder carcinoma. Br J Urol 53:320
Leissner KH, Gustavsson B (1982) Oral administration of 5-fluorouracil: renal clearance and urinary concentration in man. J Urol 128:697
Niijima T, Koiso K, Akaza H, the Japanese Urological Cancer Research Group for Adriamycin (1983) Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11 [Suppl]:S79
Omoto T, Masaki Z, Kano M, Morita I, Ariyoshi A, Ishizawa N, Momose S (1982) Postoperative prophylactic intravesical instillation of cytosine arabinoside and mitomycin C in superficial bladder tumor: follow-up study. Urology 20:510
Schulman CC, Robinson M, Denis L, Smith P, Viggiano G, De Pauw M, Dalesio O, Sylvester R, Members of the EORTC Genito-Urinary Tract Cancer Cooperative Group (1982) Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an cpipodophyllotoxin (VM 26) and TUR alone. Eur Urol 8:207
Schulman CC, Denis LJ, Oosterlinck W, De Sy W, Chatrie M, Bouffioux C, Van Caugh PJ, Van Erps P (1983) Early adjuvant Adriamycin in superficial bladder carcinoma. World J Urol 1:86
Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123:461
Soloway MS, Martino CC (1976) Prophylaxis of bladder tumor implantation: intravesical and systemic chemotherapy. Urology 7:29
Ueda T, Iguchi A, Sagiyama K, Osada Y, Ariyoshi A, Omoto T, Kumazawa J, the Kyushu University Urological Oncology Group (1987) Early intravesical instillation of Adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results. Cancer Chemother Pharmacol 20 [Suppl]:S81
UICC (1978) Bladder. In: Harmer MH (ed) TNM classification of malignant tumours, 3rd edn. UICC, Geneva, p 113
Uyama T, Yamamoto A, Aga Y, Sumiyoshi Y, Yonezawa M, Fujita J (1984) Prophylactic long-term treatment of bladder tumors with oral chemotherapy (tegafur). Urology 23:367
Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ (1982) Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 129:505
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Ueda, T., Naito, S., Iguchi, A. et al. Adjuvant chemotherapy with early intravesical instillation of Adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. Cancer Chemother. Pharmacol. 30 (Suppl 1), S31–S36 (1992). https://doi.org/10.1007/BF00686938
Issue Date:
DOI: https://doi.org/10.1007/BF00686938